Pipeline

MES1022 has completed GLP safety studies and is currently awaiting regulatory authorization to begin a first-in-man study.

Our IP consists of New Chemical Entities (NCEs) and have composition of matter patents that also cover direct synthesis methods. These patents expire 2033 to 2038. The clinical candidate has a composition of matter patent that expires 2038.